Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
文献类型：期刊论文
| 作者 | Ding, Yuqin1; Ding, Kaijing2; Yang, Hongjian1; He, Xiangming1; Mo, Wenju1; Ding, Xiaowen1 |
| 刊名 | PLOS ONE
 |
| 出版日期 | 2020-05-29 |
| 卷号 | 15 |
| ISSN号 | 1932-6203 |
| DOI | 10.1371/journal.pone.0234058 |
| 通讯作者 | Ding, Xiaowen(dingxw@zjcc.org.cn) |
| 英文摘要 | Purpose Neoadjuvant chemotherapy (NCT) is typically the initial treatment for non-early breast cancer patients. We thereby conducted a meta-analysis to explore whether dose-dense neoadjuvant chemotherapy (ddNCT) improved the long-term prognosis of patients compared to the standard NCT regimen. Methods We compared the differences in efficacy and prognosis between patients receiving standard NCT and ddNCT. We also calculated the pooled odds ratio (OR) of pathological complete response (pCR) and the pooled hazard ratio (HR) of overall survival (OS) and disease-free survival (DFS). Results Nine randomized controlled trials involving 3,724 patients from 10 published studies were included in the meta-analysis. The pooled OR for ddNCT was 1.18 (95% confidence interval (CI): 0.83-1.67, P = 0.356). A subgroup analysis in the cases with low hormone receptor expression levels showed the pCR in patients undergoing ddNCT was significantly higher than the pCR in patients undergoing standard NCT (OR = 1.36, 95% CI: 1.09-1.69, P = 0.007). There was no significant difference in DFS and OS between ddNCT and standard NCT (DFS: HR = 0.90, 95% CI: 0.79-1.02, P = 0.095; OS; HR = 0.91, 95% CI: 0.81-1.04, P = 0.160), regardless of hormone receptor expression levels. These data suggested the higher pCR rate in patients receiving ddNCT did not result in a survival benefit. Conclusions The meta-analysis demonstrated that ddNCT can significantly improve the pCR rate in patients with low hormone receptor expression levels, although patient survival was not significantly improved. The ddNCT can increase the breast-conserving rate and reduced preoperative waiting time without increasing adverse reactions. This regimen can be considered when developing an NCT plan. |
| WOS关键词 | PHASE-III TRIAL ; SURGICAL ADJUVANT BREAST ; PREOPERATIVE CHEMOTHERAPY ; INTENSIFIED CHEMOTHERAPY ; DARBEPOETIN ALPHA ; PREPARE TRIAL ; CYCLOPHOSPHAMIDE ; EPIRUBICIN ; DOCETAXEL ; THERAPY |
| 资助项目 | Natural Science Foundation of Zhejiang Province[LY18H160033] |
| WOS研究方向 | Science & Technology - Other Topics |
| 语种 | 英语 |
| WOS记录号 | WOS:000537552800226 |
| 出版者 | PUBLIC LIBRARY SCIENCE |
| 资助机构 | Natural Science Foundation of Zhejiang Province |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/103025]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Ding, Xiaowen |
| 作者单位 | 1.Chinese Acad Sci, Univ Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Dept Breast Surg,Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China 2.Zhejiang Univ, Affiliated Mental Hlth Ctr, Hangzhou Peoples Hosp 7, Dept Child Psychol, Hangzhou, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ding, Yuqin,Ding, Kaijing,Yang, Hongjian,et al. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients[J]. PLOS ONE,2020,15. |
| APA | Ding, Yuqin,Ding, Kaijing,Yang, Hongjian,He, Xiangming,Mo, Wenju,&Ding, Xiaowen.(2020).Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.PLOS ONE,15. |
| MLA | Ding, Yuqin,et al."Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients".PLOS ONE 15(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。